JP2016502526A - 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 - Google Patents

末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 Download PDF

Info

Publication number
JP2016502526A
JP2016502526A JP2015542769A JP2015542769A JP2016502526A JP 2016502526 A JP2016502526 A JP 2016502526A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A JP2016502526 A JP 2016502526A
Authority
JP
Japan
Prior art keywords
binding antibody
seq
functional fragment
binding
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502526A5 (enExample
Inventor
フィッシュマン，マーク
トゥレン，トム
イン フー，シー
イン フー，シー
バッソン，クレイグ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016502526A publication Critical patent/JP2016502526A/ja
Publication of JP2016502526A5 publication Critical patent/JP2016502526A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015542769A 2012-11-16 2013-11-14 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 Pending JP2016502526A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727334P 2012-11-16 2012-11-16
US61/727,334 2012-11-16
PCT/US2013/070042 WO2014078502A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Publications (2)

Publication Number Publication Date
JP2016502526A true JP2016502526A (ja) 2016-01-28
JP2016502526A5 JP2016502526A5 (enExample) 2016-12-28

Family

ID=49679654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542769A Pending JP2016502526A (ja) 2012-11-16 2013-11-14 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用

Country Status (6)

Country Link
US (4) US10000565B2 (enExample)
EP (1) EP2919811B1 (enExample)
JP (1) JP2016502526A (enExample)
AU (1) AU2013344796B2 (enExample)
CA (1) CA2891556A1 (enExample)
WO (1) WO2014078502A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019521161A (ja) * 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
JP2020533353A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303388A1 (en) 2015-06-04 2018-04-11 Novartis AG Use of il-1 beta binding antibodies to treat peripheral arterial disease
US20180291097A1 (en) * 2015-06-04 2018-10-11 Craig Basson Use of il-1 beta binding antibodies to treat peripheral arterial disease
AU2016302539A1 (en) 2015-07-31 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Antibody variants
EP3380611A4 (en) * 2015-11-24 2020-02-12 Commonwealth Scientific and Industrial Research Organisation PRODUCTION OF VIRUSES IN A CELL CULTURE
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
KR102880762B1 (ko) * 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法
WO2026003765A1 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528796A (ja) * 2009-05-29 2012-11-15 ゾーマ テクノロジー リミテッド ＩＬ−１β抗体およびその結合断片の心血管関連の使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
US20110110920A1 (en) 2008-03-26 2011-05-12 Orthologic Corp. Method of treating peripheral arterial disease
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009289545A1 (en) * 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for improvement of beta cell function
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
BR112012007365A2 (pt) 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
MX341579B (es) * 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2013049278A1 (en) * 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528796A (ja) * 2009-05-29 2012-11-15 ゾーマ テクノロジー リミテッド ＩＬ−１β抗体およびその結合断片の心血管関連の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AM HEART J, vol. 162, no. 4, JPN6017042993, 2011, pages 597 - 605, ISSN: 0003678327 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019521161A (ja) * 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
JP2020533353A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用

Also Published As

Publication number Publication date
EP2919811A1 (en) 2015-09-23
US20180258166A1 (en) 2018-09-13
AU2013344796B2 (en) 2016-11-10
US20200148759A1 (en) 2020-05-14
AU2013344796A1 (en) 2015-05-07
WO2014078502A1 (en) 2014-05-22
US20210317202A1 (en) 2021-10-14
CA2891556A1 (en) 2014-05-22
EP2919811B1 (en) 2018-12-26
US20160326243A1 (en) 2016-11-10
US10000565B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
AU2013344796B2 (en) Use of IL-1 beta binding antibodies for treating peripheral arterial disease
JP6250109B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
US20230265182A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
TW201315482A (zh) ＩＬ－１β結合抗體之用途
AU2024202601A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR102514173B1 (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
US20180291097A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181009